• IP And Technology Transfer

CEO Update | 10 January 2022

Welcome to the first CEO blog of 2022, one I’m delighted not to have penned from an overpriced hotel room in San Francisco – my normal place of work this time of year. A new year normally means a fresh start, but it seems the year will again be dominated by how governments and global economies will respond to the COVID-19 pandemic.

New Cambridge office to support local biologics SMEs

We’ve opened a new office at the Cambridge Innovation Park to help SMEs realise their potential and drive economic prosperity in the region’s innovation ecosystem.

CEO Update | 29 November 2021

I’m delighted to finally be able to leave the house today after my period of isolation after a positive COVID-19 test. It was such a shame not to be able to join our bioprocessing community last week for the 18th annual bioProcess UK conference but I have been enjoying looking at the photos from this great event. News over the weekend of the Omnicron variant has led to the postponement of the WTO Ministerial meeting in Geneva where waivers on the IP of COVID-19 vaccines were to be discussed, so I’m no longer expecting to see global policy set in Geneva this week.

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity.

Dr John Brown, CBE to retire as Cell and Gene Therapy Catapult’s Chairman

John Brown will retire at the end of 2021 after nine years in the role. Dr John Brown, CBE, FRSE, Chairman of Cell and Gene Therapy Catapult (CGT Catapult), will retire from the role at the end of 2021 after completing three successive terms. The Nomination Committee will establish a process, led by Hilary Newiss, to identify and appoint his successor in due course.

AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and Control

London, UK, 16th September 2021 – A 6-month collaborative project was announced today that will help to accelerate the introduction of regulated advanced gene therapies that use Adenovirus-associated vectors (AAVs).

Earlham Enterprises Ltd appoints Non-Executive directors

Earlham Enterprises Ltd has appointed two Non-Executive Directors to help push forward its work translating the cutting-edge research expertise and infrastructure at the Earlham Institute into applications that deliver impact.

Special report: patents and SPCs post-Brexit – pharma’s big opportunity?

Have you reviewed your post-Brexit patent and SPC pharma strategies? In a 32-page special report pharma patent specialists Garreth Duncan and Jennifer O'Farrell shine a spotlight on the opportunities and challenges that the pharma industry faces.

Cancer Research UK launches new ‘cancer tech accelerator’ programme

Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.

The best in AI appointed at Norwich Research Park

Scientists across Norwich Research Park institutes are part of a major integrated UK research-industry programme led by The Alan Turing Institute, seeking out the best talent in AI and data science, developing bioscience leaders and supporting the UK economy.